formation to the arch but at the same time introduced
multiple junctions, which were potential sources of type III
endoleaks.
A number of next generation devices are presently
undergoing clinical trials that may address some of the
unmet needs of this therapy. Cook (Bloomington, Ind) has
recently introduced the Pro-Form delivery system that is
intended to improve arch conformability, and in the near
future the TX2 LP (low-profile), which will